Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy)
Lalit Verma, Shweta Singh, Dinesh Talwar, Avnindra Gupta, Gauri Khare, Obuli N Ramachandran, Bhanupriya, Gaganjeet Singh Gujral, H S Harish, Nikita Gupta · 2026
Read Long-term analysis of intravitreal brolucizumab in recalcitrant cases of chronic central serous retinopathy complicated by neovascularization (pachychoroid neovasculopathy) by Lalit Verma, Shweta Singh, Dinesh Talwar, Avnindra Gupta, Gauri Khare, Obuli N Ramachandran, Bhanupriya, Gaganjeet Singh Gujral, H S Harish, Nikita Gupta (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13271552.txt.
Description
Lalit Verma and colleagues present in 2026 long-term results for brolucizumab injections in stubborn cases of chronic central serous retinopathy with new vessel growth. These eyes had already failed earlier treatments. The drug blocks a growth signal that drives fluid leakage and abnormal vessels under the retina.
The series covered 30 eyes of 25 patients treated at one center between 2021 and 2025, with injections given as needed. Retinal thickness fell sharply by six months, and vision held steady or improved in most eyes. A smaller group kept those gains at one and two years, and no side effects were recorded during the study.
Catalog record
| CREATOR | Lalit Verma, Shweta Singh, Dinesh Talwar, Avnindra Gupta, Gauri Khare, Obuli N Ramachandran, Bhanupriya, Gaganjeet Singh Gujral, H S Harish, Nikita Gupta |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |